B-type natriuretic peptide (BNP) is the first biomarker of proven value in screening for left ventricular dysfunction. The availability of point-of-care testing has escalated clinical interest and the resultant research is defining a role for BNP in the investigation and treatment of critically ill patients.
The aim of this review was to collect and assimilate current evidence regarding the use of B-type natriuretic peptide (BNP) assay in the evaluation of myocardial dysfunction in critically ill humans.
A computerized MeDLINe search was performed using the web-based entrez Pubmed database. Cita-tions were considered for review if they evaluated a relationship between BNP concentration and evidence of myocardial dysfunction in critically ill patients. The bibliographies of relevant articles were subsequently studied for articles not revealed by the initial computerized literature search. Currently explored relationships between BNP concentration and myocardial dysfunction in critically ill patients are restricted to a number of clinical states. These states provided a framework for the construction of this review. Articles that related to critically ill patients generally were reviewed together and the remaining literature was classified with regard to organ systems and disease categories.
The Cochrane library was also searched but revealed no database entries regarding BNP.
oVeRVIew
The cardiac natriuretic peptides have been actively researched over the past two decades 1, 2 . Three types of natriuretic peptides have been described in mammals-ANP (A-type or atrial natriuretic peptide), BNP (B-type or brain natriuretic peptide) and CNP (C-type natriuretic peptide) 3 . These compounds are structurally similar but genetically distinct peptides that exhibit diverse actions in cardiovascular, renal, and endocrine homeostasis.
ANP was first isolated and sequenced from human cardiac atrium in 1984 4 . Release of ANP leads to a potent natriuretic response, decreased blood pressure and increased haematocrit 5 . Although initially isolated from porcine brain 6 , BNP is preferentially produced and secreted by the cardiac myocyte in humans 7 . Although CNP has not been detected in the heart, its production by macrophages and vascular endothelium has been demonstrated 8, 9 . CNP is usually undetectable in the circulation and the autocrine/paracrine actions of the peptide in nervous system tissue and blood vessels predominate 10 . The comparative features of the three mammalian natriuretic peptides are listed in Table 1 .
BNP concentrations more closely correlate with left ventricular dysfunction than ANP concentrations 11 . BNP assay has also become more clinically accessible, including the recent development and availability of a rapid point-of-care assay. The remainder of this review will focus specifically upon BNP.
Synthesis, Storage and Secretion of BNP
The human BNP gene codes for a 134 amino acid residue BNP precursor, preproBNP. PreproBNP is cleaved to the prohormone, proBNP (108 amino acids) and a signal peptide (26 amino acids). ProBNP appears to be cleaved into the 76 amino acid N-terminal proBNP (NT-proBNP, also known by other acronyms including NT-BNP and N-BNP) and physiologically active BNP (32 amino acids) by the enzyme furin 12, 13 . BNP and NT-proBNP are produced in equimolar quantities. The synthesis of BNP is summarized in Figure 2 .
Plasma BNP concentrations in the coronary sinus are two to three times higher than those sampled from the aorta near the coronary ostium, demonstrating that BNP is secreted into the circulation through the coronary sinus from the heart 14 .
Patterns of BNP secretion imply that only small amounts are stored in granules and that increased peptide secretion is largely dependent upon increased BNP gene expression; this is in contrast to ANP which is rapidly released from atrial granules in response to atrial stretch 15 . upon ventricular overload, rapid induction of BNP gene expression reaches peak levels within one hour, resulting in prompt secretion of BNP into the circulation 16 . It has also been experimentally demonstrated that direct left ventricular wall stress-induced activation of BNP gene expression is regulated primarily at the post-transcriptional level resulting in decreased turnover, and therefore, accumulation of BNP mRNA 17 .
In health, atrial secretion of BNP predominates; when tissue weight is taken into account, ventricular BNP production accounts for approximately 30% of total cardiac production. However, in the fail- ing heart, BNP expression from the atria is largely unchanged, while expression from the ventricles more than doubles 18 .
Physiological Effects of BNP
The effects of BNP have been studied by injection of BNP into intact organisms, by exposing cells or organs to increased BNP concentrations and by altering gene expression in mice. It has been demonstrated that BNP (like ANP) binds to the natriuretic peptide receptor type A (NPR-A) resulting in increased intracellular cyclic gMP production 14 . The biological effects thus mediated include diuresis, vasodilation, inhibition of renin and aldosterone production, as well as altered cardiac and vascular myocyte growth 1 . Mice overexpressing the BNP gene exhibit systemic hypotension and bone malformations 19 . BNP knockout mice exhibit cardiac fibrosis, but not hypertension 20 . The principal physiological role of BNP appears to be protection of the cardiovascular system from the effects of volume overload 1 . Figure 3 illustrates the physiological effects of BNP.
The biological effects of NT-proBNP, if any, are currently undetermined. Likewise, the ability of uncleaved prohormone to bind to peripheral receptors is yet to be elucidated 15 .
Clearance of BNP
Natriuretic peptides are cleared from the plasma by binding natriuretic peptide receptors or by enzymatic degradation. It is believed that the non guanyl cyclase linked receptor, natriuretic peptide receptor type C (NPR-C), functions as a clearance receptor by binding and internalizing natriuretic peptides 21 . NPR-C is distributed widely in many tissues and cells including platelets, vascular smooth muscle cells, Purkinje fibres of the cardiac conduction system, glomeruli, renal collecting ducts and central nervous system 22 . BNP is also cleared from the plasma by proteolysis. The most closely studied enzyme in this respect is the extracellular membrane bound metalloprotease, neutral endopeptidase 24.11 (NeP). Compared to ANP, BNP appears to be relatively resistant to NeP degradation 23 . This may explain the relatively longer plasma half-life of BNP compared to ANP.
NT-proBNP has a longer plasma half-life than BNP. Renal excretion is currently regarded as the principal clearance mechanism of NT-proBNP 15 there is a paucity of data regarding the effect of renal impairment on BNP clearance. McLean et al demonstrated a weak but significant linear correlation between the natural logarithms of BNP concentration and creatinine concentration in a critically ill population; however, this relationship became insignificant when cardiac abnormality was excluded 24 . This supports the assertion that alterations in BNP concentration in renal failure are more likely to reflect altered cardiovascular function than altered renal clearance per se.
Plasma concentrations of BNP
In health, plasma BNP concentrations are lower than ANP concentrations. Clerico et al used a highly sensitive and specific immunoradiometric assay (IRMA) technique to measure plasma ANP and BNP in 216 healthy adults. The mean ANP value was 17.8±10.9 pg/ml with no significant difference between men (16.7±10.0 pg/ml) and women (18.8±11.7 pg/ ml). In comparison, the mean BNP value was 9.9± 9.0 pg/ml with a significant difference (P<0.0001) between men (7.7±7.1 pg/ml) and women (12.2± 10.2 pg/ml). There was a weak linear relationship between age and BNP values (r=0.254, P=0.0002).
on the other hand, mean BNP concentrations are much higher than simultaneously determined ANP levels in patients with severe heart failure 18 . BNP concentration results are assay dependent 25 .
BNP concentration can be converted from pmol/l to pg/ml by multiplying by 3.45 26 .
BNP concentrations are influenced by a number of physiological and pathological factors but, in general, elevated concentrations are consistent with left ventricular stress 27 . Physiological factors that influence circulating plasma BNP concentrations include age, bNP iN critical illNeSS gender, blood pressure, urinary salt excretion (and therefore presumably sodium intake). These changes are detailed in Table 2 .
A number of pathological conditions can also impact upon plasma BNP concentrations. Disease states associated with increased BNP concentrations include heart failure, acute myocardial infarction (first 2-5 days), essential hypertension with left ventricular hypertrophy, acute dyspnoea, pulmonary embolism, obstructive pulmonary disease, hyperthyroidism, Cushing syndrome, primary hyperaldosteronism, diabetes mellitus, liver cirrhosis with ascites, acute or chronic renal failure, subarachnoid haemorrhage and paraneoplastic syndrome [28] [29] [30] [31] [32] . BNP concentrations tend to be reduced with hypothyroidism and obesity [28] [29] [30] [31] [32] [33] . Drugs which impact upon BNP concentrations include corticosteroids, sex steroid hormones, thyroxine, diuretics, angiotensin-converting enzyme inhibitors and adrenergic agonists and antagonists 28 . elevated plasma BNP has also been associated with myocardial dysfunction secondary to chemotherapeutic treatment of malignancies 34, 35 . In general, elevated BNP concentrations tend to be associated with raised ventricular filling pressures.
BNP Assay Characteristics
Commercially available assays exist for both BNP and NT-proBNP. Despite release of equimolar amounts of BNP and NT-proBNP, assayed concentrations of BNP in plasma are lower (by a factor close to 10) 26 . This is in part due to proteolytic degradation in blood or binding to clearance receptors and partly due to the fact that BNP is less stable at room temperature than NT-proBNP. BNP has a plasma half life of approximately 20 minutes, giving it greater sensitivity for acute changes than NT-proBNP which has a half-life of 120 minutes (resulting in higher cumulative blood concentrations in patients with cardiac disease) 36 .
Clerico et al recently compared the analytical performance of five commercially available natriuretic peptide immunoassays 37 NT-proBNP was also evaluated on an elecsys® 2010 analyzer (Roche Diagnostics). Results obtained by the MeIA system were significantly different from those obtained with the other BNP assays (P<0.0001). All methods clearly differentiated between healthy individuals and patients with heart failure (mild or severe). Areas under the RoC curve (AuC) ranged from 0.865 to 0.999. The best power for separating healthy individuals from patients with mild heart failure was provided by the NT-proBNP immunoassay. All immunoassays also performed well in differentiating patients with severe heart failure from healthy individuals (AuC 0.982-0.999).
From the above, it is evident that analytical performance and diagnostic accuracy of the immunoassays should be taken into account when interpreting a BNP result.
BNP CoNCeNTRATIoNS AND MyoCARDIAL DySFuNCTIoN IN CRITICALLy ILL PATIeNTS Heterogeneous Critical Illness
Myocardial dysfunction is common in critically ill patients [36] [37] [38] . However, in this patient group, advanced age and the presence of renal failure, lung disease, pulmonary embolism, acute coronary syndromes, and diseases with high natriuretic peptide output, such as liver cirrhosis, represent potential confounders and need to be considered in the interpretation of BNP results 39. A summary of proposed BNP cut-offs described in this section is presented in Table 3 below.
A study in a surgical intensive care unit documented increased BNP concentrations in critically ill patients 40 . The highest BNP concentrations were observed in patients who underwent cardiac surgical procedures and in patients with subarachnoid haemorrhage. BNP was not a predictor of the severity of illness or mortality in this cohort.
McLean et al studied a series of 84 patients serially admitted to a combined medical and surgical intensive care unit in an Australian tertiary referral hospital over a four-week period 38 86% specificity and 96% negative predictive value. The sensitivity improved to 96% when the analysis was confined to patients ≥55 years 38 .
McLean et al followed this work with a prospective cross sectional study of 121 Australian intensive care patients 24 . The thirty-five patients (28.9%) diagnosed to have cardiac abnormalities exhibited higher BNP concentrations than those without (518±394 vs 60±98 pg/ml; P<0.001). Multivariate analyses demonstrated that the presence of cardiac abnormalities was the most significant predictor of altered BNP concentration (accounting for nearly 50% of the BNP variation). They were also able to identify the impact of gender on BNP concentrations. The area under the RoC curve was slightly less for females compared to males (92.3% vs 95.6%). The cut-off point that gave the best combination of sensitivity and specificity for males was 100 pg/ml (sensitivity=87.0%; speci-ficity=89.4%; accuracy=88.5%) For females it was 200 pg/ml (sensitivity=83.3%; specificity=84.6%; accuracy=84.0%).
Tung et al studied 49 patients with shock admitted to three intensive care units at the Massachusetts general Hospital 41 . No correlation was demonstrated between BNP concentrations and pulmonary artery occlusion pressure (PAoP) or between BNP concentrations and cardiac index (CI). However, a BNP <350 pg/ml had a negative predictive value of 95% for ruling out cardiogenic shock (defined as PAoP >18 mmHg and CI <2.2 4 min/m 2 ). The mortality rate in the lowest BNP log-quartile was 16.7%, whereas the mortality rate in the highest log-quartile was nearly 62%. The trend between log BNP quartiles and the incidence of intensice care unit mortality achieved statistical significance (P=0.006). A univariable analysis revealed age ≥70 years, pH≤7.00 and a BNP concentration in the highest log-quartile correlated with mortality. Furthermore, a multivariable analysis of these factors plus APACHe II scores (which were forced into the model) demonstrated that a BNP concentration in the highest log-quartile (relative to lowest log-quartile) was the strongest predictor of mortality (odds ratio=4.50, 95% confidence interval =1.87-99.0, P<0.001).
The correlation between BNP concentration and mortality was not supported by Cuthbertson et al, who recently conducted a prospective observational cohort of 78 consecutive intensive care patients in Scotland 42 . The study included subgroup analysis of 35 patients with severe sepsis or septic shock. Admission and 24 hour BNP and cardiac troponin I concentrations were measured; neither assay accurately predicted 30 day mortality. Although 16 (59%) of the total 27 patients and 7 (70%) of the 10 septic patients who died within 30 days had a baseline BNP of >100 pg/ml, the relationship did not achieve statistical significance (P=0.06 and 0.38 respectively). A kaplan-Meier survival curve for patients with severe sepsis or septic shock illustrated increased mortality in the patient group with an admission BNP ≤100 pg/ml; however, this relationship also failed to achieve statistical significance (P=0.06).
Dokainish et al compared tissue Doppler echocardiography and BNP in 50 intensive care and coronary care units patients with pulmonary artery catheters. Their sample included 21 intubated patients. In patients without cardiac disease (n=15), BNP >250 pg/ml had a sensitivity of 81%, a specificity of 83% and an accuracy of 82% (as determined from the area under the RoC curve) for PAoP >15 mmHg compared with 74%, 72% and 67% respectively for early transmitral velocity/tissue Doppler mitral annular early diastolic velocity (e/ea) . In patients with cardiac disease (n=35), BNP >400 pg/ml had a sensitivity of 90%, a specificity of 57% and an accuracy of 83% for PAoP >15 mmHg compared with 92%, 81% and 89% respectively for e/ea. It was concluded that BNP and e/ea have similar diagnostic accuracy for congestive heart failure (CHF) in this patient population 43 .
Cardiovascular Disease Acute decompensated cardiac failure
Published evidence supports the usefulness of BNP concentrations in the diagnosis and prognostication of patients with acute decompensated cardiac failure. each will be considered in turn.
Diagnosis: Current data suggest that measurement of BNP plasma concentration is a useful tool in the diagnosis of acute heart failure in patients presenting to an emergency department with acute dyspnoea 44 . Point-of-care BNP measurement in the emergency department discriminates well between patients with dyspnoea of cardiac and non-cardiac origin regardless of age and gender 45 . A summary of studies which propose a range of BNP cut-off values used for distinguishing myocardial dysfunction as the cause of acute dyspnoea is presented in Table 4 . The Breathing Not Properly Multinational Study was a seven-centre, prospective study of 1586 patients who presented to the emergency department between April 1999 and December 2000 with acute dyspnoea as the most prominent symptom 46 . exclusion criteria included: age less than 18 years, dyspnoea clearly attributable to another cause (e.g. trauma or cardiac tamponade), acute myocardial infarction, unstable angina (unless the predominant symptom at presentation was dyspnoea) and renal failure. eligible patients had BNP measured with a point-of-care assay upon arrival. BNP was accurate in making the diagnosis of CHF and correlated to severity of disease.
In summary, dyspnoea associated with cardiac dysfunction is highly unlikely in patients with concentrations of the peptide less than 100 pg/ml 47, 48 . Most patients with significant congestive heart failure have concentrations of the peptide greater than 400 pg/ml. In patients with concentrations of 100 to 400 pg/ml, confounding disease states including left ventricular dysfunction without volume overload, pulmonary embolism, and cor pulmonale must be ruled out 48 .
Prognostication: Plasma BNP concentrations can be useful in discriminating between normal subjects and patients in different stages of heart failure and can also be considered a prognostic indicator of long-term survival in patients with heart failure 28 . In patients with reduced ejection fraction (eF), elevated BNP was a predictor of mortality 49 and a strong independent predictor of sudden death 50 . Furthermore, serial BNP measurements during hospitalization also have prognostic usefulness. Failure of BNP levels to decline, or a delayed rise in BNP, were associated with readmission to hospital and excess mortality in patients with New york Heart Assocation (NyHA) Class III-IV heart failure 51 . Subgroup analysis of the Valsartan Heart Failure Trial also supports the conclusion that serum BNP is an important predictor of morbidity and mortality in patients with heart failure 52 .
Multimarker strategies have also been proposed as an effective means of risk assessment in patients with heart failure 53 . Heart failure patients with detectable cardiac troponin I (cTnI) and high BNP concentrations have been shown to have a 12-fold increased mortality risk compared with those with both undetectable cTnI and lower BNP 54 . Troponin T (cTnT) and BNP have also been demonstrated as independent predictors of cardiac events in heart failure 55 . BNP plasma concentrations in end-stage heart failure patients decrease in the presence of ventricular unloading by ventricular assist devices and may be indicative of recovery of ventricular function during mechanical circulatory support 56 .
Acute myocardial infarction/acute coronary syndromes
In patients referred for stress testing, BNP concentrations are elevated during, and remain elevated 30 minutes after, exercise in the presence of angiographic coronary disease compared with healthy controls. The magnitude of this BNP increase is proportional to the size of the ischaemic territory 57 . However, the utility of BNP as a marker of coronary ischemia is limited owing to its limited specificity 58 .
In patients with ST-segment elevation myocardial infarction (STeMI), higher BNP and NT-proBNP concentrations have been shown to predict a greater likelihood of death or heart failure, independent of other prognostic variables 59, 60 . when measured within 1-4 days of acute myocardial infarction, plasma BNP has been shown to be a powerful independent predictor of left ventricular function, heart failure, or death over the subsequent 14 months, and was superior to ANP, N-terminal ANP, cgMP and plasma catecholamines 61 . Anecdotal evidence suggests that in the absence of overt myocardial dysfunction in the setting of acute myocardial function, sudden elevations in BNP might forewarn of impending myocardial rupture 62 .
Recently, the prognostic value of BNP has also been extended to patients with non-STeMI 63 . elevated concentrations of BNP were associated with early death. Subgroup analysis from the TACTICS-TIMI 18 study evaluated BNP at baseline in 1,676 patients with non-STeMI randomized to early invasive versus conservative management. It demonstrated that BNP elevation was closely associated with death and progression of heart failure. Patients with elevated BNP (>80 pg/ml) were at higher risk of death at seven days and six months. Those with elevated BNP also had a fivefold higher risk of developing new congestive cardiac failure by 30 days. However, BNP concentrations were not a predictor of response to early invasive treatment 64 .
Coronary artery bypass grafting
Terazawa et al studied 27 consecutive patients undergoing coronary artery bypass grafting. Preoperative BNP concentrations differed markedly between patients in the various ASA physical status categories with higher concentrations in the ASA III and IV groups. In ASA III and IV patients, plasma BNP concentrations decreased during cardiopulmonary bypass (CPB), returning toward preoperative concentrations after bypass. The lower concentration of BNP in the ASA III and IV group during CPB may have been a reflection of decreased cardiac volume and pressure status immediately after the initiation of CPB. After bypass the BNP concentrations in this group returned toward the preoperative concentrations 65 .
Cardiac transplantation
BNP plasma concentrations are elevated in heart transplant recipients compared to the normal population 66 .
Hervas et al have also confirmed that the magnitude of BNP elevation is greater in patients with higher rejection grades on endomyocardial biopsy and greater impairment of left ventricular function 67 .
Valvular disease
Plasma BNP concentrations correlate with the severity of stenosis and degree of left ventricular dysfunction in patients with valvular aortic stenosis 68, 69 and hypertrophic obstructive cardiomyopathy 69 .
Plasma BNP concentrations also correlate with the severity of mitral regurgitation 70 .
Respiratory Disease Artificial ventilation
Scant data are available regarding the influence of altered ventilatory/intrathoracic pressures upon plasma BNP concentrations. Two published data have presented results of BNP concentration during positive pressure ventilation for acute pulmonary oedema 71, 72 . However, given the confounding factors in this study, the impact of IPPV alone on plasma BNP is difficult to decipher.
Acute pulmonary embolus
In patients with acute pulmonary embolus, it has been shown that BNP concentrations are frequently increased in the presence of right ventricular dysfunction 73, 74 . However, its role as a prognostic indicator of outcome in this setting is less clear. kruger et al did not demonstrate a correlation between BNP concentrations at presentation and in-hospital adverse events or mortality 73 . kucher et al found that low BNP concentrations (<90 pg/ml) at presentation did not guarantee an uncomplicated hospital course in patients with acute pulmonary embolus; however, a lower cut-off concentration of <50 pg/ml identified 95% of patients with a benign clinical course 75 . ten wolde et al demonstrated that high BNP concentrations (measured at presentation) were associated with increased mortality from pulmonary embolism during the three-month follow-up period 76 . It is difficult to compare studies in this area because of different population samples, different standards for diagnosing pulmonary embolism, differing BNP thresholds, different outcome assessment and different lengths of follow-up.
Acute lung injury and acute respiratory distress syndrome
There are reports of elevations in BNP in patients with acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) 77, 78 . These probably reflect the presence of right heart dysfunction. The limited sample size precludes drawing any further conclusions on the prognostic implications of elevated BNP.
Sepsis
elevated BNP is associated with septic myocardial dysfunction 79 . witthaut et al have also confirmed the association between elevated BNP and myocardial dysfunction in sepsis. However, in their study, no correlation was demonstrable between markers of inflammation or sickness severity 80 .
Subarachnoid Haemorrhage
A study of 24 patients following subarachnoid haemorrhage found that excessive secretion of BNP occurred in all subjects, unrelated to severity, stress hormone activation or markers of cardiac injury 81 . whilst elevated BNP concentrations were thought to reflect underlying myocardial dysfunction, no formal assessment of LV function was made.
Biochemical detection of myocardial dysfunction has previously been demonstrated in subarachnoid haemorrhage by Parekh and Venkatesh 82 . The sensitivity and specificity of cTnI to predict myocardial dysfunction as defined by echocardiography was documented at 100% and 91% respectively. The association between cardiac troponins and BNP in the setting of myocardial infarction and myocardial ischaemia might be found to extend into this critical care setting. Further research may address this possibility.
Acute Renal Failure and CVVHDF
There are scant data regarding the role of BNP assay in acute renal failure. As mentioned previously, elevated BNP concentrations in renal failure patients probably reflect cardiovascular changes rather than altered BNP kinetics.
Balik et al measured A-naturetic peptide (ANP) and BNP concentrations in 23 mechanically ventilated patients before and during the first 48 hours of continuous venovenous haemodiafiltration (CVVHDF). Samples were drawn both from the ports proximal and distal to the filter. The concentrations of both peptides were grossly elevated in comparison to controls (10 patients exposed to abdominal surgery). It was demonstrated that the elimination of ANP and BNP by the CVVHDF was negligible and that ANP and BNP concentrations correlated with left ventricular function even during acute renal failure and CVVHDF 83 .
Chronic Liver Disease
elevated plasma concentrations of BNP have been demonstrated in patients with cirrhosis. In a study of 51 patients with liver cirrhosis, it was found that circulating BNP was related to severity of liver disease (Child score, serum albumin, coagulation factors 2, 7, and 10, and hepatic venous pressure gradient) and to markers of cardiac dysfunction (QT interval, heart rate, plasma volume). Hepatic extraction ratios and disposal rates of plasma BNP were not significantly different in cirrhotic patients compared to controls 84 . This finding prompted the authors to conclude that elevated BNP reflects increased cardiac ventricular generation of these peptides and thus cardiac dysfunction, rather than altered hepatic disposal. Data from wong et al also appear to support this conclusion 85 .
CoNCLuSIoN
The availability of a rapid point-of-care BNP assay has escalated clinical interest and the resultant research is defining a role for BNP in the investigation and treatment of critically ill patients. BNP assay has been studied in a spectrum of clinical conditions ranging from acute dyspnoea to subarachnoid haemorrhage. Its role in diagnosis, assessment of disease severity, risk stratification and prognostic evaluation of cardiac dysfunction appears promising, but requires further elaboration. Indeed, BNP is the first biomarker to prove its value in screening for left ventricular dysfunction. However, there are a number of caveats.
First of all, the utility of BNP for evaluation of cardiac function in critically ill patients requires consensus on the optimal cut-off value/s to be used. The heterogeneity of the critically ill population appears to warrant several cut-off values depending upon demographic variables and comorbidities. Continued research may well prove the usefulness of an algorithmic approach based on a number of variables including age, gender, renal function and principal pathophysiological disturbance.
Second, the temporal changes in BNP concentrations in critically ill patients warrant further attention. Serial BNP measurements have been undertaken by a number of investigators. However, the serial BNP assays tend to be infrequent and at best can be assumed to represent a snapshot of the critically ill patient's rapidly changing haemodynamics. It is of interest that in one study, two septic patients with exceptionally high BNP concentrations, but normal baseline echocardiography, went on to develop cardiomyopathy 24 . Also, the impact of medical interventions, including fluid resuscitation and inotropic/ vasopressor support, upon serial BNP concentrations in the critically ill patient is, to date, largely undefined. To some extent the feasibility of serial BNP assay is inhibited by the financial and time constraints of frequent repetition of the assay.
Third, multiple marker strategies including BNP require further evaluation. Combinations including BNP, as a marker for myocardial dysfunction, in parallel with markers of myocyte injury, such as cardiac troponin, have been applied in certain specific conditions, including acute coronary syndromes; however, the broad base of pathophysiological states in a typical intensive care unit presents a valuable resource for proposing and testing this and other combinations of biological markers. Multi-marker strategies may prove valuable in prognostication of a variety of illnesses and perhaps even in evaluation of therapeutic interventions.
Finally, the clinical usefulness of BNP assay in the critically ill is yet to be tested with regard to altering outcome. Current research is challenged by the lack of a gold standard for the evaluation of myocardial dysfunction. each clinically available standard has its own limitations 86 . Scant data exist to justify the use of BNP assay to alter therapy. The possibility that the outcomes of critically ill patients may be improved by clinical decisions based upon BNP assay is speculative and further research in all of the aforementioned areas will be important to address this.
In conclusion, it appears that BNP assay can offer complementary information to conventional approaches for the evaluation of cardiac dysfunction and clinical disease. It is expected that further research will reinforce the value of BNP assay for evaluating myocardial dysfunction in patients with life-threatening illness.
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